CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.
March 10th 2023
Cabometyx plus Tecentriq failed to improve progression-free survival in patients with kidney cancer.
February 28th 2023
The drug duo Lenvina plus Keytruda led to improved outcomes for patients with advanced renal cell carcinoma, extended follow-up of the CLEAR trial showed.
February 21st 2023
A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.
February 20th 2023
The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research.
December 29th 2022
Discovering different genetic mutations to target ... continues to add to the excitement.
December 28th 2022
Going through cancer is a marathon, not a sprint.
December 27th 2022
As a part of its “Speaking Out” video series, CURE® spoke with Meryl Uranga, on behalf of KidneyCAN, about the importance of working as a team with their clinicians and getting educated before making decisions.
December 26th 2022
One expert explains how the road to cancer drug development isn’t a smooth one, but progress can be made nonetheless.
December 23rd 2022
FDA-approved immunotherapies offer patients with metastatic or recurrent sarcomatoid RCC more treatment choices and improved outcomes.
December 20th 2022
HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease.
December 19th 2022
Take a look at the top advancements and most popular articles about kidney cancer from the year 2022.
December 15th 2022
In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.
When Sean Korbitz was a 20-year-old college student, his life trajectory changed with a rare cancer diagnosis, resulting in the removal of 40 tumors; fifteen years later, a new drug made him feel like a “medical miracle.”
December 13th 2022
Newer drugs for kidney cancer have proven extremely effective but can cause unwanted symptoms that affect safety and quality of life.
December 5th 2022
A kidney cancer diagnosis may negatively affect a patient’s mental health; however, exercise may help put them at ease.
November 7th 2022
As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga, a patient advocate, about integrative care for kidney cancer.
As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga, a patient advocate, about the side effects associated with kidney cancer treatment.
As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga about the importance of patients being their own advocate when communicating with their physician.
October 31st 2022
I was misdiagnosed twice before receiving my kidney cancer diagnosis, and along the way, I learned the importance of expert doctors and clinical trials.
October 19th 2022
Once seen as a malignancy resistant to typical treatments such as chemotherapy, metastatic kidney cancer has come a long way in the past 20 years.
October 12th 2022
Twenty years of FDA approvals for the treatment of metastatic kidney cancer have allowed patients to live longer.
September 28th 2022
The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.
September 20th 2022
Although patients treated with the combination did not have significant improvements in survival, telaglenastat and Cabometyx did not increase the rate of side effects in patients.
September 12th 2022
The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.
August 30th 2022
An expert explains the different types of kidney cancer surgeries, and what patients can expect to experience after the procedure.
July 29th 2022
Findings from the CheckMate-914 trial showed that Opdivo plus Yervoy did not meet the study’s main goal of disease-free survival for patients with localized renal cell carcinoma, a type of kidney cancer.
July 27th 2022
A new treatment group within the PYNNACLE clinical trial is set to evaluate a novel drug plus Keytruda in patients with p53 Y220C-mutant locally advanced or metastatic solid tumors.
July 1st 2022
From “General Hospital” star Cameron Mathison discussing his cancer experience to Dame Deborah James and Hells Angels founder Sonny Barger dying of the disease, here’s what happened in the cancer space this week.
June 29th 2022
Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.
Facing My Mortality from Cancer Made Me Grateful for Loved Ones
From Bedside to the Starting Line, a Patient Bonds With Her Oncologist Through Running
From Couch Crashing to Cancer
Radiation May Not Affect Long-Term Breast Cancer Survival, But Expert Warns Patients to Discuss Treatment With Providers